title: Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
abstract: Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.
authors.affiliation: The Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: Vera
authors.initials: V
authors.lastname: Eremina
authors.forename: Susan E
authors.initials: SE
authors.lastname: Quaggin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D051379:Mice; D023421:Models, Animal; D011507:Proteinuria / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D015398:Signal Transduction / Q000235:genetics; D057049:Thrombotic Microangiopathies / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A